Report cover image

Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 197 Pages
SKU # APRC20552438

Description

Summary

According to APO Research, The global Hypoxia Inducible Factor 1 Alpha Inhibitor market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hypoxia Inducible Factor 1 Alpha Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Hypoxia Inducible Factor 1 Alpha Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Hypoxia Inducible Factor 1 Alpha Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Hypoxia Inducible Factor 1 Alpha Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Hypoxia Inducible Factor 1 Alpha Inhibitor include Vascular Biogenics Ltd., Transcriptogen Ltd, Sorrento Therapeutics, Inc., RXi Pharmaceuticals Corporation, Peloton Therapeutics, Inc., OncoImmune, Inc., InterMed Discovery GmbH, F. Hoffmann-La Roche Ltd. and Cerulean Pharma, Inc., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hypoxia Inducible Factor 1 Alpha Inhibitor, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Hypoxia Inducible Factor 1 Alpha Inhibitor, also provides the sales of main regions and countries. Of the upcoming market potential for Hypoxia Inducible Factor 1 Alpha Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hypoxia Inducible Factor 1 Alpha Inhibitor sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Hypoxia Inducible Factor 1 Alpha Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Hypoxia Inducible Factor 1 Alpha Inhibitor sales, projected growth trends, production technology, application and end-user industry.

Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Company

Vascular Biogenics Ltd.
Transcriptogen Ltd
Sorrento Therapeutics, Inc.
RXi Pharmaceuticals Corporation
Peloton Therapeutics, Inc.
OncoImmune, Inc.
InterMed Discovery GmbH
F. Hoffmann-La Roche Ltd.
Cerulean Pharma, Inc.
CASI Pharmaceuticals Inc.
Aileron Therapeutics, Inc.
Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Type

CRLX-101
CASI-2ME2
BC-001
Others
Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Application

Solid Tumor
Colorectal Cancer
Acute Myelocytic Leukemia
Others
Hypoxia Inducible Factor 1 Alpha Inhibitor Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hypoxia Inducible Factor 1 Alpha Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hypoxia Inducible Factor 1 Alpha Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hypoxia Inducible Factor 1 Alpha Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hypoxia Inducible Factor 1 Alpha Inhibitor market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Hypoxia Inducible Factor 1 Alpha Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hypoxia Inducible Factor 1 Alpha Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Hypoxia Inducible Factor 1 Alpha Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

197 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size, 2020 VS 2024 VS 2031
1.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Size Estimates and Forecasts (2020-2031)
1.4 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Estimates and Forecasts (2020-2031)
1.5 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market Dynamics
2.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Trends
2.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Drivers
2.3 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Opportunities and Challenges
2.4 Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Restraints
3 Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Manufacturers
3.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Manufacturers (2020-2025)
3.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Manufacturers (2020-2025)
3.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Average Sales Price by Manufacturers (2020-2025)
3.4 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Manufacturers, Product Type & Application
3.7 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Market CR5 and HHI
3.8.2 Global Top 5 and 10 Hypoxia Inducible Factor 1 Alpha Inhibitor Players Market Share by Revenue in 2024
3.8.3 2024 Hypoxia Inducible Factor 1 Alpha Inhibitor Tier 1, Tier 2, and Tier 3
4 Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Type
4.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Type Introduction
4.1.1 CRLX-101
4.1.2 CASI-2ME2
4.1.3 BC-001
4.1.4 Others
4.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Type
4.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Type (2020-2031)
4.2.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Market Share by Type (2020-2031)
4.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Type
4.3.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Type (2020-2031)
4.3.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Market Share by Type (2020-2031)
5 Hypoxia Inducible Factor 1 Alpha Inhibitor Market by Application
5.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Application Introduction
5.1.1 Solid Tumor
5.1.2 Colorectal Cancer
5.1.3 Acute Myelocytic Leukemia
5.1.4 Others
5.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Application
5.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Application (2020-2031)
5.2.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Market Share by Application (2020-2031)
5.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Application
5.3.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Application (2020-2031)
5.3.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Market Share by Application (2020-2031)
6 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region
6.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region (2020-2031)
6.2.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Region (2020-2025)
6.2.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region
7.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region
7.1.1 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region (2020-2025)
7.1.3 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue by Region (2026-2031)
7.1.4 Global Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue (2020-2031)
7.2.2 North America Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue (2020-2031)
7.3.2 Europe Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue (2020-2031)
7.4.2 Asia-Pacific Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Hypoxia Inducible Factor 1 Alpha Inhibitor Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Vascular Biogenics Ltd.
8.1.1 Vascular Biogenics Ltd. Comapny Information
8.1.2 Vascular Biogenics Ltd. Business Overview
8.1.3 Vascular Biogenics Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Vascular Biogenics Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.1.5 Vascular Biogenics Ltd. Recent Developments
8.2 Transcriptogen Ltd
8.2.1 Transcriptogen Ltd Comapny Information
8.2.2 Transcriptogen Ltd Business Overview
8.2.3 Transcriptogen Ltd Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Transcriptogen Ltd Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.2.5 Transcriptogen Ltd Recent Developments
8.3 Sorrento Therapeutics, Inc.
8.3.1 Sorrento Therapeutics, Inc. Comapny Information
8.3.2 Sorrento Therapeutics, Inc. Business Overview
8.3.3 Sorrento Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Sorrento Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.3.5 Sorrento Therapeutics, Inc. Recent Developments
8.4 RXi Pharmaceuticals Corporation
8.4.1 RXi Pharmaceuticals Corporation Comapny Information
8.4.2 RXi Pharmaceuticals Corporation Business Overview
8.4.3 RXi Pharmaceuticals Corporation Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 RXi Pharmaceuticals Corporation Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.4.5 RXi Pharmaceuticals Corporation Recent Developments
8.5 Peloton Therapeutics, Inc.
8.5.1 Peloton Therapeutics, Inc. Comapny Information
8.5.2 Peloton Therapeutics, Inc. Business Overview
8.5.3 Peloton Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Peloton Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.5.5 Peloton Therapeutics, Inc. Recent Developments
8.6 OncoImmune, Inc.
8.6.1 OncoImmune, Inc. Comapny Information
8.6.2 OncoImmune, Inc. Business Overview
8.6.3 OncoImmune, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 OncoImmune, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.6.5 OncoImmune, Inc. Recent Developments
8.7 InterMed Discovery GmbH
8.7.1 InterMed Discovery GmbH Comapny Information
8.7.2 InterMed Discovery GmbH Business Overview
8.7.3 InterMed Discovery GmbH Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 InterMed Discovery GmbH Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.7.5 InterMed Discovery GmbH Recent Developments
8.8 F. Hoffmann-La Roche Ltd.
8.8.1 F. Hoffmann-La Roche Ltd. Comapny Information
8.8.2 F. Hoffmann-La Roche Ltd. Business Overview
8.8.3 F. Hoffmann-La Roche Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 F. Hoffmann-La Roche Ltd. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.8.5 F. Hoffmann-La Roche Ltd. Recent Developments
8.9 Cerulean Pharma, Inc.
8.9.1 Cerulean Pharma, Inc. Comapny Information
8.9.2 Cerulean Pharma, Inc. Business Overview
8.9.3 Cerulean Pharma, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Cerulean Pharma, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.9.5 Cerulean Pharma, Inc. Recent Developments
8.10 CASI Pharmaceuticals Inc.
8.10.1 CASI Pharmaceuticals Inc. Comapny Information
8.10.2 CASI Pharmaceuticals Inc. Business Overview
8.10.3 CASI Pharmaceuticals Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 CASI Pharmaceuticals Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.10.5 CASI Pharmaceuticals Inc. Recent Developments
8.11 Aileron Therapeutics, Inc.
8.11.1 Aileron Therapeutics, Inc. Comapny Information
8.11.2 Aileron Therapeutics, Inc. Business Overview
8.11.3 Aileron Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Aileron Therapeutics, Inc. Hypoxia Inducible Factor 1 Alpha Inhibitor Product Portfolio
8.11.5 Aileron Therapeutics, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Value Chain Analysis
9.1.1 Hypoxia Inducible Factor 1 Alpha Inhibitor Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Hypoxia Inducible Factor 1 Alpha Inhibitor Production Mode & Process
9.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Hypoxia Inducible Factor 1 Alpha Inhibitor Distributors
9.2.3 Hypoxia Inducible Factor 1 Alpha Inhibitor Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.